PharmaEssentia Corp (6446):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PharmaEssentia Corp (6446) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8013
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PharmaEssentia Corp (PharmaEssentia) is a developer of therapeutic products for the treatment of human diseases. The company’s pipeline product includes P1101, a new generation PEG-Interferon-alpha-2b which is developed using PEGylation technology platform. Its pegylation technology platform is designed to increase the protein drug’s efficacy by prolonging its circulation in the bloodstreamd. PharmaEssentia’s products are used in the therapeutic areas of dermatology, hematology, infectious diseases and oncology. The company also develops oncology drug for various carcinomas, including pancreatic cancer, non-small cell lung cancer, bladder cancer and breast cancer. It collaborates with biotechnology companies, university research institutes, and pharmaceutical companies. PharmaEssentia is headquartered in Taipei, Taiwan.

PharmaEssentia Corp (6446) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PharmaEssentia Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 10
Equity Offering 12
PharmaEssentia Raises USD88 Million in Public Offering of Shares 12
PharmaEssentia Raises USD20.5 Million in Rights Offering of Shares 13
PharmaEssentia Corp – Key Competitors 14
PharmaEssentia Corp – Key Employees 15
PharmaEssentia Corp – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PharmaEssentia Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PharmaEssentia Corp, Deals By Therapy Area, 2012 to YTD 2018 8
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 10
PharmaEssentia Raises USD88 Million in Public Offering of Shares 12
PharmaEssentia Raises USD20.5 Million in Rights Offering of Shares 13
PharmaEssentia Corp, Key Competitors 14
PharmaEssentia Corp, Key Employees 15
PharmaEssentia Corp, Other Locations 16

List of Figures
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[PharmaEssentia Corp (6446):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ricoh Leasing Company, Ltd.:企業の戦略・SWOT・財務情報
    Ricoh Leasing Company, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ricoh Leasing Company, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Credit Saison Co., Ltd.
    Credit Saison Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Credit Saison Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Sujana Universal Industries Ltd. (SUJANAUNI):企業の財務・戦略的SWOT分析
    Sujana Universal Industries Ltd. (SUJANAUNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Severstal:企業の戦略・SWOT・財務情報
    Severstal - Strategy, SWOT and Corporate Finance Report Summary Severstal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • BioArctic AB (BIOA B):製薬・医療:M&Aディール及び事業提携情報
    Summary BioArctic AB (BioArctic), formerly BioArctic Neuroscience AB, is a biopharma company that develops new immunotherapeutic treatments for patients with central nervous system disorders. The company develops drugs for neurological disorders such as Parkinson’s disease, Alzheimer’s disease and s …
  • Mytilineos Holdings Sa
    Mytilineos Holdings Sa - Strategy, SWOT and Corporate Finance Report Summary Mytilineos Holdings Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Sillajen Biotherapeutics (215600):製薬・医療:M&Aディール及び事業提携情報
    Summary Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The company’s pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that …
  • Grendene S.A. (GRND3):企業の財務・戦略的SWOT分析
    Grendene S.A. (GRND3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Multan Electric Power Co Ltd:企業の戦略的SWOT分析
    Multan Electric Power Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • New Zealand Pharmaceuticals Ltd:企業の戦略的SWOT分析
    New Zealand Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Telecom Argentina S.A.
    Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report Summary Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Marvel Entertainment LLC:企業の戦略的SWOT分析
    Marvel Entertainment LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Tokio Marine & Nichido Fire Insurance Co., Ltd.:企業のM&A・事業提携・投資動向
    Tokio Marine & Nichido Fire Insurance Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tokio Marine & Nichido Fire Insurance Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descript …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • The Macerich Co:企業のM&A・事業提携・投資動向
    The Macerich Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Macerich Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Tesaro Inc (TSRO)-製薬・医療分野:企業M&A・提携分析
    Summary Tesaro Inc (Tesaro) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates, comprising rolapitant, niraparib, and the product candidates under its immuno-oncology platform. VARUBI, the company’s first commercial product is …
  • Tizona Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tizona Therapeutics Inc (Tizona Therapeutics) is an immunology company which develops treatments for cancer and autoimmune disorders. Its lead product candidate anti-CD39 antibody inhibits the breakdown of excessive ATP released from dying tumor cells to immune suppressive adenosine leading …
  • AMC Airlines:企業の戦略・SWOT・財務情報
    AMC Airlines - Strategy, SWOT and Corporate Finance Report Summary AMC Airlines - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Babcock Power Inc:企業の戦略的SWOT分析
    Babcock Power Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Lixte Biotechnology Holdings Inc (LIXT):企業の財務・戦略的SWOT分析
    Lixte Biotechnology Holdings Inc (LIXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆